Vaxart (VXRT) Stock Overview
A clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
VXRT Community Fair Values
Create NarrativeSee what 25 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Vaxart, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.65 |
| 52 Week High | US$0.84 |
| 52 Week Low | US$0.26 |
| Beta | 1.18 |
| 1 Month Change | 3.49% |
| 3 Month Change | 10.53% |
| 1 Year Change | 60.99% |
| 3 Year Change | -52.41% |
| 5 Year Change | -89.86% |
| Change since IPO | -92.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| VXRT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -14.0% | 0.1% | 2.6% |
| 1Y | 61.0% | 35.5% | 26.2% |
Return vs Industry: VXRT exceeded the US Biotechs industry which returned 42% over the past year.
Return vs Market: VXRT exceeded the US Market which returned 31.1% over the past year.
Price Volatility
| VXRT volatility | |
|---|---|
| VXRT Average Weekly Movement | 11.0% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: VXRT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: VXRT's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 65 | Steven Lo | vaxart.com |
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; COVID-19 Vaccine, which is in Phase 2b clinical trial for the treatment of SARS-CoV-1, SARS-CoV-2, and Middle East respiratory syndrome coronavirus; Seasonal Influenza vaccine, which is in Phase 2 clinical trial, to treat H1N1 Influenza; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral.
Vaxart, Inc. Fundamentals Summary
| VXRT fundamental statistics | |
|---|---|
| Market cap | US$168.82m |
| Earnings (TTM) | US$37.10m |
| Revenue (TTM) | US$255.61m |
Is VXRT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VXRT income statement (TTM) | |
|---|---|
| Revenue | US$255.61m |
| Cost of Revenue | US$201.58m |
| Gross Profit | US$54.03m |
| Other Expenses | US$16.94m |
| Earnings | US$37.10m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.15 |
| Gross Margin | 21.14% |
| Net Profit Margin | 14.51% |
| Debt/Equity Ratio | 4.5% |
How did VXRT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/11 14:50 |
| End of Day Share Price | 2026/05/11 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vaxart, Inc. is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Roger Song | Jefferies LLC |
| null null | Oppenheimer & Co. Inc. |